The Latest Cardiac and Vascular News
CLICHY, France–(BUSINESS WIRE)–CorWave, a French company that develops and manufactures innovative cardiac assist devices, held the grand opening of its new facility on the banks of the Seine in Clichy, next to Paris, on Monday, October 9th. The company occupies over 2,400m² of production, laboratory, and office space, bringing together […]
GALWAY, Ireland–(BUSINESS WIRE)–WhiteSwell, a company pioneering a new paradigm in the treatment of acute decompensated heart failure (ADHF), announced today positive initial results from its ongoing DELTA-HF trial evaluating the WhiteSwell eLym™ System. The data were presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2023 in […]
ZURICH, Switzerland, Oct. 09, 2023 (GLOBE NEWSWIRE) — Nanoflex Robotics AG, a remote robotic surgical company based in Switzerland, announced it has received a second grant from Innosuisse, Switzerland’s Innovation Agency this year. The receipt of the second grant brings Nanoflex Robotics’ total non-dilutive grant funding received from Innosuisse this […]
SOUTH SAN FRANCISCO, Calif. and CLEVELAND, Oct. 09, 2023 (GLOBE NEWSWIRE) — Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today released new data for TN-301 at the 2023 Heart […]
NAPERVILLE, Ill., Oct. 9, 2023 /PRNewswire/ — Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure (HF), announced it has received Investigational Device Exemption (IDE) approval from the FDA for a subsequent multicenter study, PROACTIVE-HF 2, which will evaluate the company’s Cordella Sensor for pulmonary artery […]
SANTA CLARA, Calif., Oct. 8, 2023 /PRNewswire/ — Axon Therapies, a private company focused on addressing a root cause of heart failure, today announced 6-month results of the REBALANCE-HF randomized, blinded feasibility trial of the Splanchnic Ablation for Volume Management (SAVM) procedure for heart failure with preserved ejection fraction (HFpEF). The main objectives of the […]
SAN DIEGO–(BUSINESS WIRE)–Rejuvenate Bio, today announced new preclinical efficacy data for RJB-0402, a gene therapy targeting key disease-mediating pathways. RJB-0402 demonstrated efficacy in a mouse model of arrhythmogenic cardiomyopathy (ACM), an inherited disease caused by mutations in one of several genes encoding desmosomal proteins. A single dose of RJB-0402 was […]
RALEIGH, N.C., Oct. 6, 2023 /PRNewswire/ — Contego Medical Inc., a company dedicated to improving patient outcomes and procedural efficiency in the treatment of carotid and peripheral vascular disease, today announced enrollment of the first patient in the PERFORMANCE III Trial. PERFORMANCE III is a prospective, multicenter trial aimed at further evaluating […]
JUPITER, FL, Oct. 06, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Marizyme, Inc. (OTCQB:MRZM) (“Marizyme” or the “Company”), a global medical technology company focused on the development of products to address unmet clinical needs, today announced that it was granted a de novo from the U.S. Food and Drug Administration (FDA) for its […]
LONDON–(BUSINESS WIRE)–LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, announced its Board of Directors has appointed J. Christopher Barry to the Board, effective today. Barry will serve on the Audit and Compliance Committee. Andrea Saia, who has served as a Director since 2016, will retire from the LivaNova Board […]
